Medco: Follow-on biotech drugs could drive market growth

11/23/2008 | Reuters

Medco Health Solutions told investors Friday that follow-on biotech medicines could help the company and its customers save money if a regulatory pathway for such products is created. Assuming that an approval process would start in 2011, Amgen's Aranesp, Genentech's Avastin and Johnson & Johnson's Remicade would be among top-selling drugs that may face follow-on competition between 2013 and 2017, Medco said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT